about
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysisThe effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysisPegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirAn eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemiaEffect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders.Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects.Optimal treatment of social phobia: systematic review and meta-analysis.The single dose pharmacokinetics of ribavirin in subjects with chronic liver diseasePharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.Model-based drug development.Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis.Meta-analysis of relapse prevention antidepressant trials in depressive disorders.Study design and patient characteristics and outcome in acute mania clinical trials.Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersThe effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling.Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits.Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.Anti-anxiety drugs reduce conflict-specific "theta"--a possible human anxiety-specific biomarker.Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study.The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce.Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.Dose- and exposure-response to ketamine in depression.Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
P50
Q22252432-5CF50E0A-226D-4B3D-999C-E5FA5D54128FQ28472672-5903EE63-BF6B-468D-AA0B-9B40084439B4Q30620502-80BFCF5A-45D4-42F1-A817-A76AA6B92224Q33155841-CA6B0BD2-3B90-47D2-B0FD-8E5AB363FC84Q33485538-B20A5A6E-716F-4DA7-8D6A-8FADCCE4B00AQ33628834-83D2E230-B6FF-4D7E-9A5F-64184B9103F0Q33630473-0FD3300F-7B78-44CB-AA24-31638E17D9ACQ33696575-57635081-D0D6-4D81-91A7-CC4A865299A3Q34700305-4EB6BE2D-3BB5-4EF7-AE0E-1A1243D6EFBDQ34976469-C66C3E33-00BE-482F-B9F8-76373174AC3AQ35027450-16F5C62C-88F9-4DCD-875B-B1546B7486E0Q35183615-E32D06A6-06C7-4D81-A82B-2B7B9E3F169CQ35235578-CCDABE06-3ABC-4A5E-AD94-5B085E1A702BQ35802787-2B9D6D18-40D3-4317-89A5-B5F150F3DFF8Q35825645-B67D5383-CB88-4632-9A46-7565AD2B9A43Q35997293-E74516BE-88A5-4AD5-A401-6EC8EAB7F215Q36055167-899B8528-F8E3-43A8-8CC8-221DB7172B5AQ36536413-3DCCAE97-34B8-434A-9644-D099F81B6DC7Q36830686-4CCDEE3E-FDF9-47C2-80A7-92854E3E6AF7Q37471054-F0B5C3E3-FEEA-438D-AC36-47DF3AF1DCE2Q37555366-E43B4C6C-0CD4-436E-BB55-A7BE20D8EB9AQ37773366-91AFBB33-3BB6-4D2D-B1E3-DF56C18BB156Q37858609-A79728EF-9643-498D-8C03-7FFBC23E52DDQ41673269-E8EC1AA7-E7E6-4775-9F04-577D67AD2BAAQ42283777-F56B6635-E750-4D36-BB63-13845CC4771FQ42553398-1BD67F84-380A-4470-86EB-1A92C21D437CQ42655585-68AA2274-F29E-40F6-85F3-BC1126614EE9Q43000537-628564EB-67E8-4681-A8FA-323CF9D8D37AQ43241662-4BD96F09-0469-4793-8988-7C2461C2C705Q44026920-C53885CB-FFBE-47F4-929D-728990E66A0DQ44129882-094932B4-9361-4CE4-A242-7311523CC19EQ44167269-78332B1B-58CD-4D3B-BA7E-A67BC5AFE2D4Q45249086-69FFCEDE-0E83-4CAB-B4B4-C2E7120926BBQ46107330-B246F0D5-6FC0-4B6E-82AA-58193A4FB9E5Q46233521-2550C6FC-DB00-45C3-BECE-606146C7AD23Q46497127-C7F0D137-FFB2-431B-A8F0-6C95FB8251D3Q47909182-9CF78A9C-F5B6-42EE-A324-5179BF8D82E3Q48173177-62CD2946-FA59-47BB-A0A7-931971991D2AQ48272087-9D4D30A7-52C6-41DF-8EED-3489171237E8Q48311153-BA7BD23E-E616-4BAD-B30B-C161381781C3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul Glue
@ast
Paul Glue
@en
Paul Glue
@es
Paul Glue
@fr
Paul Glue
@nl
Paul Glue
@sl
type
label
Paul Glue
@ast
Paul Glue
@en
Paul Glue
@es
Paul Glue
@fr
Paul Glue
@nl
Paul Glue
@sl
prefLabel
Paul Glue
@ast
Paul Glue
@en
Paul Glue
@es
Paul Glue
@fr
Paul Glue
@nl
Paul Glue
@sl
P106
P1153
7005452278
P21
P31
P496
0000-0002-7305-2800